Over a Decade of Innovation

We are pioneering a new era of medicines

Transforming the lives of patients living with serious diseases


BREAKING NEWS

The U.S. FDA approves the CRISPR/Cas9 gene-edited treatment, co-developed with Vertex Pharmaceuticals, in sickle cell disease.

Learn More

Rapidly translating a revolutionary technology into therapies

Innovation that matters

Rapidly translating a revolutionary technology into therapies

Learn more about gene editing
Science crispr x

Pushing the bounds of science

We are pioneers of the CRISPR technology and at the forefront of what’s next

Learn more about CRISPR-X

Committed to patients

Developing gene-based medicines with the potential to transform the lives of people with serious diseases

Patient Advocacy

Learn more about our programs

We have established a diverse portfolio across a broad range of disease areas including hemoglobinopathies, oncology, diabetes and cardiovascular disease.

View Pipeline
Hemoglobinopathies program

Hemoglobinopathies

Aiming to treat sickle cell disease and β-thalassemia with gene-edited blood stem cells.

Learn more
Immuno oncology program

Immuno-Oncology

Creating the next generation of cell therapies for cancer enabled by gene editing.

Learn more
Regenerative medicine program

Regenerative Medicine

Broadening the applications of stem cells through gene editing.

Learn more
In vivo program

In Vivo

Editing cells inside the body to treat diseases.

Learn more

CRISPR Therapeutics Corporate Presentation

View our corporate presentation to learn more about our company.

Download Here

You are now leaving the CRISPR Therapeutics website.

CRISPR Therapeutics is not responsible for the content or availability of third-party sites.

Continue